# Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers

> **NCT02268825** · PHASE1 · TERMINATED · sponsor: **University of Utah** · enrollment: 39 (actual)

## Conditions studied

- Advanced GI Cancer

## Interventions

- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02268825
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-23
- **Primary completion:** 2017-01-25
- **Final completion:** 2017-06-26
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Merck requested to change MK-3475 dosing schedule; PI decided to close instead
- **Last updated:** 2018-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268825, "Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02268825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*